Compare Quest Diagnostics Inc (DGX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nvidia Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Nvidia Corp trades at $229.39 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 218.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Nvidia Corp for 115 Days on average.
| DGX | NVDA | |
|---|---|---|
Market Cap | $25.48B | $5.57T |
Volume | 941,866 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $247.45 | $239.27 |
52-Week Low | $173.49 | $165.17 |
Typical Hold Time | 56 Days | 115 Days |
Enterprise Value | $31.23B | $5.54T |
Dividend Yield | 1.49% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
NVIDIA (NVDA) trades at $229.28, down 3.4% today, but maintains strong fundamentals with revenue surging to $130.5B in 2025 and net income reaching $72.88B. The stock shows a bullish technical signal with support at $228 and resistance at $235. Recent earnings beats and a 75.95% analyst buy rating highlight continued growth momentum despite the day's decline.
Outlook remains positive with a consensus price target of $339.17, offering 48% upside. Key risks include increased competition in AI chips and market volatility, but NVIDIA's dominant market position and accelerating AI demand support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
